<DOC>
	<DOCNO>NCT01125800</DOCNO>
	<brief_summary>Phase I dose-escalation study characterize safety , tolerability , pharmacokinetics pharmacodynamics LDE225 give orally daily dose schedule child recurrent refractory medulloblastoma , tumor potentially dependent Hedgehog signal pathway . Phase II study ass preliminary efficacy adult pediatric patient recurrent refractory MB .</brief_summary>
	<brief_title>A Phase I Dose Finding Safety Study Oral LDE225 Children Phase II Portion Assess Preliminary Efficacy Recurrent Refractory MB</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Hepatoblastoma</mesh_term>
	<criteria>Phase I Patients aged ≥12 month &lt; 18 year , Phase II Patients ≥12 month Phase I Histologically confirm diagnosis medulloblastoma , rhabdomyosarcoma , neuroblastoma , hepatoblastoma , high grade glioma , osteosarcoma , progress despite treatment standard therapy , standard treatment available ( patient brainstem gliomas exclude ) . Phase II Histologically confirm diagnosis recurrent relapse medulloblastoma least one measurable lesion . Performance Status : Karnofsky ≥60 % patient &gt; 10 yr , Lansky ≥50 patient less equal 10 yr Protocoldefined renal , liver bone marrow function Negative pregnancy test start study treatment . If child bear potential must use 'highly effective ' method contraception . All patient must consent provide tumor sample Systemic anticancer treatment within 2 week prior first dose ( 6 week nitrosourea , mitomycin monoclonal antibody ) . Focal radiotherapy within 4 week prior first dose , full spinal radiotherapy within 3 month first dose . Unresolved toxicity great CTCAE grade 1 previous anticancer therapy radiotherapy ( exclude neurotoxicity , alopecia , ototoxicity , lymphopenia specification eligibility criterion study ) , incomplete recovery previous surgery , unless agree Novartis Principal Investigator ( PI ) document . Major surgery , serious illness traumatic injury within 2 week start study therapy . Patients anticipate require major surgery within first 2 cycle treatment . Patients require nasogastric tube drug administration ( Gtubes permit ) Impaired cardiac function Pregnant breastfeeding female Impairment gastrointestinal ( GI ) function GI disease Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Recurrent ,</keyword>
	<keyword>refractory ,</keyword>
	<keyword>medulloblastoma ,</keyword>
	<keyword>rhabdomyosarcoma ,</keyword>
	<keyword>neuroblastoma ,</keyword>
	<keyword>hepatoblastoma ,</keyword>
	<keyword>astrocytoma ,</keyword>
	<keyword>child ,</keyword>
	<keyword>pediatric ,</keyword>
	<keyword>hedgehog pathway inhibitor , adult</keyword>
</DOC>